Affinage

FZD6

Frizzled-6 · UniProt O60353

Length
706 aa
Mass
79.3 kDa
Annotated
2026-06-09
49 papers in source corpus 20 papers cited in narrative 20 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/6 claims corpus-supported (83%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FZD6 is a Frizzled-family Wnt receptor that acts as a context-dependent switch between canonical Wnt/β-catenin signaling and non-canonical planar cell polarity (PCP) signaling, governing tissue patterning, cell motility, and tumor behavior [PMID:14747478, PMID:36368445, PMID:bio_10.1101_2024.06.25.600357]. In its founding biochemical characterization, FZD6 functioned as a negative regulator of canonical Wnt/β-catenin signaling: it did not affect β-catenin stabilization, nuclear TCF4 levels, or β-catenin·TCF4 complex formation, but instead activated the TAK1–NLK cascade to block TCF/LEF binding to target promoters, with both N- and C-terminal sequences required for this repressive activity (PMID:14747478). This TAK1–NLK-dependent restraint of canonical signaling is reiterated in glioblastoma, where FZD6 engages CaMKII–TAK1–NLK signaling (PMID:27698350). FZD6 also operates as a PCP receptor: in endothelial cells, shear stress drives spatial reorganization of Fzd6 at the plasma membrane, where mutual exclusion of Fzd6 and Vangl1 at junctions coordinates collective cell alignment to flow and proper vessel sprouting [PMID:bio_10.1101_2024.06.25.600357]. Across cancers FZD6 shows strongly context-dependent roles—restraining proliferation and invasion in some settings (melanoma invasion, prostate stemness) while supporting growth in others; in melanoma it is required for invasion and metastasis but not proliferation (PMID:36368445, PMID:29867083), and in prostate cancer it supports tumor growth and DNA double-strand break repair through SRC–STAT3 activity and a PLK1–WEE1 axis (PMID:41286306). In the nervous system, Fzd6 functions as a positive regulator of canonical Wnt/β-catenin signaling in hippocampus, where its loss produces depressive-like behavior and reduced hippocampal proliferation (PMID:37321345). In humans, a homozygous nonsense mutation (p.E584X) in FZD6 causes autosomal-recessive nail dysplasia, with FZD6 strongly expressed in the ventral nail matrix and nail bed (PMID:22211385).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2004 High

    Established the foundational and counterintuitive mechanism by which FZD6 restrains rather than activates canonical Wnt signaling, defining its action downstream of the β-catenin destruction complex.

    Evidence Wnt reporter assays, co-expression with HFz1/Dvl1/stabilized β-catenin, EMSA for TCF/LEF-DNA binding, and terminal deletion mutagenesis in cell lines

    PMID:14747478

    Open questions at the time
    • Does not resolve how FZD6 selects between canonical repression and PCP activation
    • Ligand specificity for the repressive output not defined
    • No structural basis for the N-/C-terminal requirement
  2. 2011 Medium

    Connected FZD6 to neuropsychiatric regulation by identifying it as a CREB target whose hippocampal suppression produces affective phenotypes.

    Evidence ChIP-microarray for CREB occupancy and viral-vector knockdown in rat hippocampus with behavioral testing

    PMID:21937024

    Open questions at the time
    • Does not establish which Wnt arm mediates the behavioral effect
    • Downstream effectors in hippocampus not defined
  3. 2012 Medium

    Linked FZD6 to a human Mendelian disease, demonstrating its essential role in nail patterning consistent with PCP-dependent tissue guidance.

    Evidence Genome-wide linkage, Sanger sequencing identifying a homozygous p.E584X nonsense mutation, and immunohistochemistry on nail sections

    PMID:22211385

    Open questions at the time
    • Does not test the mutant protein's signaling output directly
    • Mechanism connecting FZD6 loss to nail dysplasia not resolved
  4. 2016 Medium

    Placed FZD6 in defined oncogenic signaling circuits, showing context-specific coupling to TAK1-NLK and downstream STAT3/NF-κB in GBM and non-canonical Wnt suppression of proliferation in gastric cancer.

    Evidence Pathway perturbation and subtype expression analysis in GBM cells; gain/loss-of-function with proliferation/migration and miR-21 target validation in gastric cancer cells

    PMID:27347343 PMID:27698350

    Open questions at the time
    • Opposing directionality across tumor types not mechanistically reconciled
    • Direct ligand engagement not defined in these models
  5. 2019 Medium

    Identified physical partners and RNA-based regulators that route FZD6 toward β-catenin nuclear translocation in specific cancers, reframing FZD6 as a positive Wnt effector in these contexts.

    Evidence Co-IP of NPTX2-FZD6 with siRNA rescue in colorectal cancer; RNA-protein interaction of lncRNA PCAT-1 with FZD6 plus rescue in AML cells

    PMID:30833544 PMID:31814913

    Open questions at the time
    • Reciprocal interaction validation limited
    • How partner binding switches FZD6 output toward canonical signaling unknown
  6. 2021 Medium

    Demonstrated ligand-driven receptor complex formation, showing WNT10B activates Wnt signaling through a FZD6 receptor complex in leukemia.

    Evidence Reciprocal Co-IP of WNT10B/FZD6, shRNA silencing, and PORCN inhibition (LGK974) with proliferation readouts in T-ALL

    PMID:33497493

    Open questions at the time
    • Stoichiometry and co-receptor composition of the complex not defined
    • Downstream effector branch not fully mapped
  7. 2022 High

    Established a clean genetic requirement for FZD6 in metastatic behavior, dissociating its role in invasion from proliferation.

    Evidence CRISPR/Cas9 knockout with in vitro invasion assays and in vivo Pten/BRaf melanoma model linked to canonical Wnt/EMT markers

    PMID:36368445

    Open questions at the time
    • Molecular link between FZD6 and the EMT program not fully resolved
    • Whether canonical or non-canonical signaling drives invasion not disentangled
  8. 2023 High

    Defined FZD6 as a positive canonical Wnt regulator in hippocampus and established a behavioral phenotype from its loss, contrasting with its repressive role in other systems.

    Evidence CRISPR/Cas9 Fzd6-Δ5 mouse model with behavioral batteries, Ki67/PCNA immunofluorescence, and Wnt pathway qRT-PCR/Western blot

    PMID:37321345

    Open questions at the time
    • Mechanism of cell-type/context-dependent directional switching unresolved
    • Receptor ligand in hippocampus not identified
  9. 2024 Medium

    Provided direct mechanistic insight into FZD6 PCP function by showing shear-stress-driven membrane reorganization and mutual exclusion with Vangl1 coordinates endothelial polarity.

    Evidence Live imaging, subcellular localization, biomimetic flow chambers, zebrafish vessel studies, and Vangl1 loss-of-function with Fzd6 localization readout (preprint)

    PMID:bio_10.1101_2024.06.25.600357

    Open questions at the time
    • Preprint not yet peer-reviewed
    • Molecular basis of Fzd6/Vangl1 mutual exclusion not defined
    • Link to vascular disease not established
  10. 2025 High

    Uncovered a non-Wnt-centric oncogenic role for FZD6 in supporting DNA double-strand break repair and tumor growth in prostate cancer through kinase signaling.

    Evidence shRNA knockdown, patient-derived xenografts, γH2AX/DSB repair reporter assays, kinome-wide CRISPR screen, and SRC/STAT3/WEE1/PLK1 analysis

    PMID:41286306

    Open questions at the time
    • How a Frizzled receptor couples to SRC-STAT3 and PLK1-WEE1 mechanistically unresolved
    • Direct versus indirect control of DSB repair not separated
  11. 2025 Medium

    Expanded the context-dependent FZD6 outputs to chemoresistance, adipogenesis, and tissue aging through β-catenin and transcriptional/post-transcriptional regulation.

    Evidence FZD6 KD/OE with pyroptosis and 5-FU resistance readouts in CRC; miR-199a-5p target validation and adipogenesis rescue in BM-MSCs; HOXC10 ChIP at the FZD6 promoter in fibroblast senescence models

    PMID:40810359 PMID:41198743 PMID:41268215

    Open questions at the time
    • Directionality of FZD6 on β-catenin differs across these contexts without unifying mechanism
    • Causal versus correlative regulation in some models incompletely separated

Open questions

Synthesis pass · forward-looking unresolved questions
  • The central unresolved question is what determines whether FZD6 represses or activates canonical Wnt/β-catenin signaling, and how a single receptor coordinates this switch with PCP signaling and kinase-driven outputs across tissues.
  • No structural model of FZD6 in distinct signaling states
  • Ligand/co-receptor combinations dictating output not systematically mapped
  • Mechanism coupling FZD6 to SRC-STAT3 and PLK1-WEE1 unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0098772 molecular function regulator activity 2
Localization
GO:0005886 plasma membrane 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-1266738 Developmental Biology 2
Partners
NPTX2VANGL1WNT10B

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 HFz6 acts as a negative regulator of canonical Wnt/β-catenin signaling: it does not activate the canonical pathway in response to Wnt-1 or Wnt-5a group ligands, and represses Wnt-3a-induced canonical signaling when co-expressed with HFz1. The repression operates downstream of the β-catenin destruction complex (does not affect β-catenin stabilization or TCF4 nuclear levels or β-catenin·TCF4 complex formation), but inhibits TCF/LEF binding to target DNA as shown by EMSA. HFz6 activates the TAK1-NLK pathway, which blocks TCF/LEF binding to target promoters. N'- and C'-terminal sequences of HFz6 are required for its repressive activity. Reporter assays (canonical Wnt luciferase), co-expression with HFz1/Dvl1/stabilized β-catenin(S33Y)/LiCl, EMSA for TCF/LEF-DNA binding, deletion mutagenesis of HFz6 termini, Western blotting for β-catenin and TCF4 levels The Journal of biological chemistry High 14747478
2016 FZD6 activates CaMKII-TAK1-NLK signaling downstream, which attenuates canonical Wnt pathway activity while promoting STAT3 and NF-κB signaling, thereby driving a mesenchymal GBM phenotype. This places FZD6 in a regulatory circuit with TCF4-miR-125b/miR-20b. Pathway inhibition/activation assays, gene expression analysis in PN vs MES GBM subtypes, functional validation targeting differentially enriched pathways Nature communications Medium 27698350
2016 FZD6 represses gastric cancer cell proliferation and migration via activation of the non-canonical Wnt pathway, and activation of non-canonical Wnt by FZD6 in turn ameliorates (reduces) canonical Wnt pathway activity. FZD6 is a direct target of miR-21, which suppresses FZD6 expression. Gain/loss-of-function experiments in gastric cancer cells, proliferation and migration assays, pathway reporter assays, miR-21 target validation American journal of translational research Medium 27347343
2019 NPTX2 physically interacts with FZD6 to promote β-catenin nuclear translocation in colorectal cancer cells, resulting in increased MYC, cyclin D1, snail, and N-cadherin and decreased E-cadherin. siRNA knockdown of FZD6 almost completely reversed NPTX2-induced proliferative effects. Co-immunoprecipitation (physical interaction between NPTX2 and FZD6), siRNA knockdown of FZD6, β-catenin nuclear translocation assay, in vitro and in vivo proliferation/metastasis assays Cell death & disease Medium 30833544
2019 lncRNA PCAT-1 directly interacts with FZD6 protein to regulate its stability; PCAT-1 activates the Wnt/β-catenin signaling pathway in an FZD6-dependent manner in AML cells. Overexpression of FZD6 partially abolishes the effects of PCAT-1 silencing on AML cell proliferation and apoptosis. RNA-protein interaction assay, gain/loss-of-function experiments, cell proliferation and apoptosis assays, Wnt/β-catenin pathway readouts American journal of translational research Medium 31814913
2021 In T-ALL, WNT10B drives Wnt pathway activation primarily through the FZD6 receptor complex via ligand binding. shRNA-mediated silencing of FZD6 or pharmacological inhibition of WNT secretion (LGK974 PORCN inhibitor) reduces WNT10B/FZD6 protein complex formation, impairs intracellular effectors, and reduces leukemic cell expansion. Co-immunoprecipitation (WNT10B/FZD6 protein complex), shRNA gene silencing, small molecule (LGK974) inhibition, Wnt pathway effector analysis, cell proliferation assays Hematological oncology Medium 33497493
2022 FZD6 knockout in melanoma does not affect cell proliferation but significantly reduces invasive ability in vitro and dramatically reduces lung metastasis in the Pten/BRaf mouse model. The invasive phenotype is mechanistically linked to canonical Wnt signaling and the epithelial-mesenchymal transition pathway. CRISPR/Cas9 knockout of FZD6, in vitro invasion assays, in vivo melanoma mouse model (Pten/BRaf), Wnt signaling and EMT marker analysis The Journal of investigative dermatology High 36368445
2023 FZD6 knockdown (CRISPR/Cas9 Fzd6-Δ5 mice) produces depressive-like behavior (increased immobility in FST, reduced sucrose preference, decreased locomotion, reduced open-arm time in EPM) and reduces hippocampal cell proliferation (reduced Ki67+ and PCNA+ cells). Mechanistically, FZD6 KD decreases Gsk3β mRNA, phosphorylated GSK3β, and cytoplasmic β-catenin in hippocampus, establishing FZD6 as a positive regulator of canonical Wnt/β-catenin signaling in this context. CRISPR/Cas9 KO mouse model, behavioral tests (OFT, EPM, FST, TST, SPT), immunofluorescence for Ki67/PCNA, qRT-PCR and Western blot for Wnt pathway components Journal of advanced research High 37321345
2025 FZD6 knockdown in prostate cancer suppresses growth in vitro and in vivo, impairs DNA double-strand break repair (measured by γH2AX foci resolution and DSB repair reporter assays), and reduces activities of SRC kinase and STAT3. DNA damage repair deficiency is mechanistically mediated through WEE1 downregulation via PLK1. A kinome-wide CRISPR-Cas9 screen reveals FZD6 inhibition sensitizes cells to PKMYT1 inhibition. shRNA knockdown, patient-derived xenograft models, γH2AX foci assay, DSB repair reporter assay, kinome-wide CRISPR-Cas9 screen, SRC/STAT3 activity assays, WEE1/PLK1 protein analysis Oncogene High 41286306
2025 FZD6 overexpression promotes nuclear translocation of β-catenin, reduces NLRP3/caspase-1/GSDMD-mediated classical pyroptosis, and increases 5-fluorouracil resistance in colorectal cancer cells. Conversely, FZD6 knockdown decreases nuclear β-catenin, enhances pyroptosis, and reduces 5-FU resistance. Lentiviral FZD6 KD/OE, immunofluorescence and Western blot for nuclear β-catenin, microscopy and electron microscopy for pyroptosis morphology, CCK-8/colony formation/EdU assays Carcinogenesis Medium 40810359
2024 In endothelial cells, shear stress triggers spatial reorganization of Fzd6 at the plasma membrane. The mutual exclusion of PCP proteins Fzd6 and Vangl1 at cell junctions augments differential junctional and cytoskeletal dynamics along the flow axis. This PCP signaling coordinates collective endothelial cell alignment to flow direction and proper vessel sprouting. Live imaging, subcellular fractionation/localization, biomimetic flow chambers, in vivo zebrafish vessel studies, mathematical modeling, loss-of-function for Vangl1 with Fzd6 localization readout bioRxivpreprint Medium bio_10.1101_2024.06.25.600357
2011 Viral vector-mediated inhibition of Fzd6 expression in the rat hippocampus produced anxiety- and depressive-like effects in behavioral models of depression, establishing Fzd6 as a functional CREB target gene regulated by chronic electroconvulsive seizure in the hippocampus. Chromatin immunoprecipitation-microarray (CREB binding), viral vector-mediated gene knockdown in rat hippocampus, behavioral models of depression/anxiety Biological psychiatry Medium 21937024
2012 A homozygous nonsense mutation (p.E584X) in FZD6 causes autosomal-recessive nail dysplasia. Immunohistochemistry shows FZD6 is strongly expressed in the ventral nail matrix and nail bed, placing it as a critical regulator of nail plate growth and guidance. The mutation maps to the C-terminal domain, consistent with earlier findings that C-terminal sequences are required for FZD6 signaling function. Genome-wide linkage analysis, Sanger sequencing for mutation identification, immunohistochemistry on nail sections The British journal of dermatology Medium 22211385
2018 WNT5A (a ligand highly expressed in liver non-TICs) activates FZD6 to drive Wnt/β-catenin signaling and liver tumor-initiating cell (TIC) self-renewal. FZD6 is the only Frizzled receptor overexpressed during liver tumorigenesis among FZD1-10. The lncRNA lncFZD6 recruits the BRG1-embedded SWI/SNF chromatin remodeling complex to the FZD6 promoter to activate FZD6 transcription; FZD6 drives liver TIC self-renewal in an FZD6-dependent manner. Expression profiling of FZD1-10, ChIP for BRG1 at FZD6 promoter, co-immunoprecipitation of lncFZD6-BRG1 complex, loss-of-function and rescue experiments for FZD6 in liver TIC self-renewal and tumor initiation Oncogene Medium 29535420
2018 Luteolin upregulates FZD6 transcriptionally in prostate cancer cells, and FZD6 upregulation inhibits canonical Wnt signaling and suppresses prostate cancer stemness. FZD6 identified as a tumor suppressor that can abolish PCa stemness. iTRAQ-based quantitative proteomics, transcriptional upregulation analysis, Wnt signaling reporter assays, prostate cancer stem cell marker assays, proliferation and self-renewal assays Scientific reports Medium 29867083
2021 FZD6 silencing in cervical cancer cells retards proliferation, invasion, and EMT, and inactivates Wnt/β-catenin signaling. Mechanistically, FTO demethylase stabilizes lncRNA HOXC13-AS (by reducing m6A modification), which then augments FZD6 expression through CBP-mediated H3K27 acetylation at the FZD6 locus. qRT-PCR, CCK-8, colony formation, Transwell assays; luciferase reporter, FISH, subcellular fractionation, ChIP, RNA immunoprecipitation for mechanism Journal of B.U.ON. Medium 34564982
2025 HOXC10 transcription factor directly targets the FZD6 promoter to reduce FZD6 expression, thereby activating Wnt/β-catenin signaling and delaying skin fibroblast senescence and skin aging. Single-cell transcriptomics, ChIP for HOXC10 at FZD6 promoter, overexpression/KD in fibroblasts, senescence assays, in vivo aging models Research (Washington, D.C.) Medium 41268215
2024 In CIA rat fibroblast-like synoviocytes, Fzd6 expression is elevated and drives NF-κB signaling activation (p-p65/p65 and p-IκBα/IκBα) along with pro-inflammatory cytokine expression (COX-2, IL-8, TNF-α). Fengshi Liuhe Decoction downregulates Fzd6 and suppresses this Fzd6/NF-κB signaling axis. qPCR and Western blot comparison of normal vs CIA rat FLS, ELISA for inflammatory cytokines, nuclear translocation assay for NF-κB p65 Gene Low 38710294
2023 In colorectal cancer cells, linc00659 binds to IGF2BP1 (validated by RNA pulldown and RIP), and IGF2BP1 stabilizes FZD6 mRNA (validated by RNA stability assay), thereby activating Wnt/β-catenin signaling and promoting CRC cell proliferation. RNA pulldown and RNA immunoprecipitation for linc00659-IGF2BP1 interaction, RNA stability assay for FZD6 mRNA, Wnt/β-catenin Western blot, in vivo xenograft The journal of gene medicine Medium 38009760
2025 FZD6 negatively regulates adipogenesis of bone marrow mesenchymal stem cells: FZD6 expression is decreased during adipogenic differentiation and in aplastic anemia BM-MSCs, and FZD6 overexpression alleviates miR-199a-5p-driven adipogenic differentiation. FZD6 is a direct target of miR-199a-5p (validated experimentally). miR-199a-5p inhibition experiments, luciferase reporter assay for miR-199a-5p targeting FZD6, FZD6 overexpression rescue of adipogenesis phenotype, expression profiling Scientific reports Medium 41198743

Source papers

Stage 0 corpus · 49 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2004 The human Frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt. beta-catenin signaling cascade. The Journal of biological chemistry 118 14747478
2017 Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage. Oncogenesis 96 28737757
2016 A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. Nature communications 83 27698350
2011 FZD6 is a novel gene for human neural tube defects. Human mutation 81 22045688
2020 Mesenchymal stem cell-derived extracellular vesicles suppress the fibroblast proliferation by downregulating FZD6 expression in fibroblasts via micrRNA-29b-3p in idiopathic pulmonary fibrosis. Journal of cellular physiology 66 32557673
2019 Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/FZD6/Wnt/β-catenin pathway in pancreatic cancer. Cancer management and research 62 31118816
2018 LncFZD6 initiates Wnt/β-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation. Oncogene 61 29535420
2019 NPTX2 promotes colorectal cancer growth and liver metastasis by the activation of the canonical Wnt/β-catenin pathway via FZD6. Cell death & disease 55 30833544
2015 FZD6 expression is negatively regulated by miR-199a-5p in human colorectal cancer. BMB reports 54 25772759
2018 Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics. Scientific reports 46 29867083
2021 FTO-stabilized lncRNA HOXC13-AS epigenetically upregulated FZD6 and activated Wnt/β-catenin signaling to drive cervical cancer proliferation, invasion, and EMT. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 42 34564982
2016 FZD6, targeted by miR-21, represses gastric cancer cell proliferation and migration via activating non-canonical wnt pathway. American journal of translational research 41 27347343
2020 Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/β-catenin signaling pathway in bladder cancer. Journal of experimental & clinical cancer research : CR 34 32677984
2012 FZD6 encoding the Wnt receptor frizzled 6 is mutated in autosomal-recessive nail dysplasia. The British journal of dermatology 34 22211385
2015 Regulatory variant in FZD6 gene contributes to nonsyndromic cleft lip and palate in an African-American family. Molecular genetics & genomic medicine 23 26436110
2023 circMMD reduction following tumor treating fields inhibits glioblastoma progression through FUBP1/FIR/DVL1 and miR-15b-5p/FZD6 signaling. Journal of experimental & clinical cancer research : CR 22 36932454
2013 Immunoreactivity of Wnt5a, Fzd2, Fzd6, and Ryk in glioblastoma: evaluative methodology for DAB chromogenic immunostaining. Brain tumor pathology 22 23748645
2011 Analysis of target genes regulated by chronic electroconvulsive therapy reveals role for Fzd6 in depression. Biological psychiatry 21 21937024
2019 lncRNA PCAT-1 interacting with FZD6 contributes to the malignancy of acute myeloid leukemia cells through activating Wnt/β-catenin signaling pathway. American journal of translational research 18 31814913
2022 FZD6 Promotes Melanoma Cell Invasion but Not Proliferation by Regulating Canonical Wnt Signaling and Epithelial‒Mesenchymal Transition. The Journal of investigative dermatology 14 36368445
2010 Downregulation of Fzd6 and Cthrc1 and upregulation of olfactory receptors and protocadherins by dietary beta-carotene in lungs of Bcmo1-/- mice. Carcinogenesis 14 20472610
2021 CircSmg5 stimulates the osteogenic differentiation of bone marrow mesenchymal stem cells by targeting the miR-194-5p/Fzd6 axis and beta-catenin signaling. Environmental toxicology 12 34850997
2023 CRISPR/Cas9 based gene editing of Frizzled class receptor 6 (FZD6) reveals its role in depressive symptoms through disrupting Wnt/β-catenin signaling pathway. Journal of advanced research 11 37321345
2021 miR-199b-5p enhances the proliferation of medullary thymic epithelial cells via regulating Wnt signaling by targeting Fzd6. Acta biochimica et biophysica Sinica 11 33313638
2021 The flavonoid luteolin suppresses infantile hemangioma by targeting FZD6 in the Wnt pathway. Investigational new drugs 11 33411210
2014 Polymorphisms in FZD3 and FZD6 genes and risk of neural tube defects in a northern Han Chinese population. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 11 24816679
2024 Inhibition of miR-199b-5p reduces pathological alterations in osteoarthritis by potentially targeting Fzd6 and Gcnt2. eLife 10 38770735
2016 Isolated recessive nail dysplasia caused by FZD6 mutations: report of three families and review of the literature. Clinical and experimental dermatology 10 27786367
2021 FZD6 triggers Wnt-signalling driven by WNT10BIVS1 expression and highlights new targets in T-cell acute lymphoblastic leukemia. Hematological oncology 9 33497493
2021 Role of Fzd6 in Regulating the Osteogenic Differentiation of Adipose-derived Stem Cells in Osteoporotic Mice. Stem cell reviews and reports 9 34041696
2012 A novel missense mutation in the gene FZD6 underlies autosomal recessive nail dysplasia. The British journal of dermatology 9 22861124
2019 A possible founder mutation in FZD6 gene in a Turkish family with autosomal recessive nail dysplasia. BMC medical genetics 8 30642273
2023 Long non-coding RNA linc00659 promotes tumour progression by regulating FZD6/Wnt/β-catenin signalling pathway in colorectal cancer via m6A reader IGF2BP1. The journal of gene medicine 6 38009760
2023 SOX8 promotes tumor growth and metastasis through FZD6-dependent Wnt/β-catenin signaling in colorectal carcinoma. Heliyon 5 38046159
2025 FZD6 promotes 5-fluorouracil resistance through inhibiting pyroptosis in colorectal cancer. Carcinogenesis 4 40810359
2024 Effects of Fzd6 on intestinal flora and neuroinflammation in lipopolysaccharide-induced depression-like mice. Journal of affective disorders 4 39643213
2022 Construction of Fzd6Q152E mice through CRISPR/Cas9 technology and their reproduction and identification. Molecular biology reports 4 35980530
2019 A novel FZD6 mutation revealed the cause of cleft lip and/or palate in a Chinese family. Genes & diseases 4 32884998
2021 The Expression of Selected Wnt Pathway Members (FZD6, AXIN2 and β-Catenin) in Canine Oral Squamous Cell Carcinoma and Acanthomatous Ameloblastoma. Animals : an open access journal from MDPI 3 34072517
2024 Fengshi Liuhe Decoction treatment for rheumatoid arthritis via the Fzd6/NF-κB signaling axis. Gene 2 38710294
2017 A novel pathogenic variant in the FZD6 gene causes recessive nail dysplasia in a large Iranian kindred. Journal of dermatological science 2 28545862
2025 Dual Functions and Therapeutic Potential of FZD6 in Biliary Atresia. Digestive diseases and sciences 1 40618286
2025 Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer. Oncogene 1 41286306
2023 Knockdown of circEXOC6 inhibits cell progression and glycolysis by sponging miR-433-3p and mediating FZD6 in glioma. Translational neuroscience 1 37554539
2022 Comprehensive Genomic Analysis for Identifying FZD6 as a Novel Diagnostic Biomarker for Acute Myeloid Leukemia. Computational and mathematical methods in medicine 1 36452482
2026 Inhibition of PD-L1 in tubular epithelial cells attenuates renal fibrosis by suppressing TGFβR1 and FZD6 signaling. International immunopharmacology 0 41990703
2025 FZD6 mediates the contributing role of miR-199a-5p in the adipogenesis of bone marrow mesenchymal stem cells derived from aplastic anemia. Scientific reports 0 41198743
2025 HOXC10 Protects from Skin Aging by Targeting the FZD6/Wnt/β-Catenin Signaling Pathway. Research (Washington, D.C.) 0 41268215
2019 First Report of a Known Pathogenic Variant in the FZD6 Gene, in an Iranian Family with Recessive Nail Dysplasia: A Case Report. Iranian journal of public health 0 31497560

Missed literature

Know a paper Affinage missed for FZD6? Flag it for the maintainers and the community.

No submissions yet.